Hormone Replacement Therapy for Menopause: Benefits, Risks, and Who Should Consider It

Hormone replacement therapy is the most effective treatment available for menopausal symptoms, yet it remains one of the most misunderstood and under-prescribed interventions in women's health. For two decades following the Women's Health Initiative (WHI) publication in 2002, HRT prescribing plummeted globally as patients and physicians alike interpreted the study's findings as a general warning against hormonal therapy. That interpretation was wrong in ways that have been meticulously documented by menopause researchers — and the consequence has been unnecessary suffering for millions of women who would have benefited. This article explains what HRT is, what it does, what the evidence actually shows about its risks, and how to think about whether it is appropriate for you.

What Hormone Replacement Therapy Is

HRT replaces the hormones that decline during and after menopause — primarily estrogen, and in women with an intact uterus, progesterone (or a synthetic progestogen). The rationale is straightforward: most menopausal symptoms are driven by estrogen deficiency, and replacing estrogen to near-physiological levels resolves most of them. Estrogen is also essential for bone maintenance, cardiovascular health in younger women, and the integrity of genitourinary tissues. The drop in estrogen at menopause is not a minor hormonal shift; it is a major physiological transition that affects virtually every organ system.

Types of HRT

Estrogen-Only vs. Combined Therapy

Women who have had a hysterectomy (surgical removal of the uterus) can use estrogen alone. Estrogen unopposed by progesterone in a woman with a uterus substantially increases the risk of endometrial (uterine) cancer — studies show a 5 to 10-fold increase with prolonged use — so combined therapy is essential when the uterus is present. Combined therapy pairs estrogen with either a progestogen taken continuously (causing no monthly bleed in most women) or cyclically (causing a regular withdrawal bleed). The choice between these regimens depends on where a woman is in the menopausal transition; sequential cycling is typically preferred in perimenopause.

Delivery Routes: Oral, Patch, Gel, and Ring

How estrogen is delivered matters significantly for both efficacy and safety. Oral estrogen is absorbed through the gut, passes through the liver (first-pass metabolism), and stimulates hepatic production of clotting factors and C-reactive protein — effects that are associated with a small increase in venous thromboembolism (VTE) risk. Transdermal estrogen — delivered via patch, gel, or spray — bypasses the liver entirely, does not affect clotting factors at standard doses, and carries no measurable increase in VTE risk. This is not a minor distinction; for women with cardiovascular risk factors or a history of migraine with aura, transdermal delivery is strongly preferred. Vaginal estrogen (cream, ring, tablet, or pessary) acts locally on genitourinary tissues with negligible systemic absorption and can be used even by women who cannot take systemic HRT. The vaginal ring (Estring) releasing low-dose estradiol is an option for genitourinary symptoms without meaningful systemic effect.

Progestogen Choices

Not all progestogens are the same. Synthetic progestogens (medroxyprogesterone acetate, norethisterone, levonorgestrel) differ from micronized progesterone, the form that is bioidentical to the progesterone made by the human corpus luteum. The WHI used medroxyprogesterone acetate (MPA); subsequent research suggests that micronized progesterone carries a more favorable risk profile, particularly for breast cancer risk and cardiovascular effects. UK and international guidelines now recommend micronized progesterone as the preferred progestogen where available (branded as Utrogestan in the UK, Prometrium in the US).

The WHI Study: What It Showed and How It Was Misread

The Women's Health Initiative published its first findings in 2002, reporting increased rates of breast cancer, coronary heart disease, stroke, and pulmonary embolism in women randomized to conjugated equine estrogen plus MPA. The trial was stopped early. Media coverage was immediate and alarming. HRT prescriptions fell by 50 percent within two years.

What was widely missed: the average age of participants in the WHI was 63, approximately 12 years past the average age of menopause. Many had cardiovascular disease or cardiovascular risk factors. The formulation used (oral conjugated equine estrogen with MPA) is not representative of modern transdermal therapy with micronized progesterone. And critically, the WHI estrogen-only arm (for women who had had a hysterectomy) showed no increased breast cancer risk at 7 years and suggested a possible reduction in breast cancer incidence — a finding that received far less attention than the combined arm results.

The "timing hypothesis," also called the window of opportunity, emerged from re-analyses of WHI data and independent studies. It shows clearly that the cardiovascular effects of HRT differ dramatically depending on when it is started. Women who start HRT within 10 years of menopause onset or before age 60 tend to show neutral-to-beneficial cardiovascular effects. Women who start HRT more than 10 years after menopause, when atherosclerosis may already be established, show different and potentially adverse effects. This timing-dependent pattern explains many of the apparent contradictions between the WHI and earlier observational studies that had suggested cardioprotective effects of HRT.

Breast Cancer Risk in Context

The breast cancer risk associated with combined HRT is real and should be discussed honestly. However, it must be understood in context. The WHI found that after 5 years of combined HRT use, there were approximately 8 additional breast cancer cases per 10,000 women per year — a relative risk increase of about 26 percent, but an absolute risk that is small. To put this in perspective: drinking one alcoholic drink per day increases breast cancer risk by approximately the same amount. Obesity increases it by more. The estrogen-only arm of WHI (for women without a uterus) did not show an increased breast cancer risk.

More recent data from the Collaborative Group meta-analysis (2019) showed somewhat higher relative risks for combined HRT than the WHI, particularly with longer duration of use. This analysis should be reviewed with individual risk in mind: a woman with a baseline 10-year breast cancer risk of 3 percent who uses combined HRT for 5 years has a revised risk of approximately 3.7 percent. Whether that incremental risk is acceptable in exchange for 5 years of significantly improved quality of life is a decision that belongs to the patient, not to a blanket policy.

Who Benefits Most

Women experiencing moderate to severe vasomotor symptoms (hot flashes, night sweats) have the most robust evidence of benefit from HRT. Symptom relief is typically excellent: HRT reduces hot flash frequency by 75 to 90 percent. Sleep quality, mood, cognitive function, and sexual function improve with vasomotor symptom resolution and, in some women, through direct neurological effects of estrogen. Bone protection is well established; HRT significantly reduces fracture risk and is considered a first-line option for osteoporosis prevention in women under 60. Genitourinary symptoms respond to both systemic and local estrogen. Emerging evidence suggests cardiovascular benefit when HRT is started early, and some studies support reduced risk of type 2 diabetes with early HRT use.

Who Should Not Use HRT

Absolute contraindications to systemic HRT include unexplained vaginal bleeding (until the cause is established), known or suspected estrogen-sensitive breast or uterine cancer (with some nuance for certain cancer types discussed on an individual basis), active or recent arterial thromboembolic disease (recent heart attack or stroke), active venous thromboembolism, untreated endometrial hyperplasia, and pregnancy. Women with a history of breast cancer can in many cases use vaginal estrogen for genitourinary symptoms after discussion with their oncologist, but systemic HRT is generally avoided. Women with a history of VTE can often use transdermal HRT, which does not increase clotting risk, but should be assessed individually.

Bioidentical Hormones: What the Term Actually Means

The term "bioidentical" is heavily marketed by compounding pharmacies to imply safety superior to pharmaceutical HRT. Bioidentical simply means that the hormone is structurally identical to the one produced by the human body — and micronized estradiol and micronized progesterone used in regulated pharmaceutical products are already bioidentical by this definition. Compounded "bioidentical" hormone preparations are not standardized, are not subject to the same regulatory scrutiny as pharmaceutical products, and their safety has not been established in clinical trials. Claims that compounded preparations are safer than pharmaceutical ones are not supported by evidence. The appropriate choice between pharmaceutical products should be based on evidence, delivery route, and individual clinical context — not on marketing language.

Non-Hormonal Alternatives

For women who cannot or choose not to use HRT, several evidence-based non-hormonal options exist for vasomotor symptoms. SSRIs and SNRIs — particularly paroxetine (the only FDA-approved non-hormonal treatment for menopausal hot flashes, under the brand name Brisdelle), venlafaxine, and escitalopram — reduce hot flash frequency by approximately 50 to 60 percent. Gabapentin and pregabalin reduce vasomotor symptoms, particularly when sleep disruption is prominent, at doses of 300 mg three times daily for gabapentin. Fezolinetant (Veozah), a selective neurokinin 3 receptor antagonist approved by the FDA in 2023, targets the thermoregulatory mechanism directly and reduces hot flash frequency by 60 to 70 percent in clinical trials, with a favorable safety profile. Cognitive behavioral therapy adapted specifically for menopausal symptoms reduces the subjective burden of hot flashes significantly, even when it does not change their frequency — a clinically meaningful outcome. Clonidine has modest evidence and significant side effects that limit its use.

How Long to Use HRT

The old guideline of using HRT for the shortest possible time at the lowest effective dose was derived from a blanket risk-minimization interpretation of the WHI. Current guidance from the Menopause Society (formerly NAMS) and the British Menopause Society is more nuanced: duration should be individualized based on indications, risk profile, and patient preference. For some women, particularly those with early menopause or significant osteoporosis risk, longer-term use is appropriate. For women using HRT primarily for quality-of-life symptom relief, annual reassessment is reasonable. There is no arbitrary upper age limit on HRT use; the decision to continue or stop should be based on ongoing risk-benefit assessment.

When to See a Doctor

If you are experiencing menopausal symptoms that are affecting your sleep, mood, quality of life, or sexual function, you deserve a clinician who can assess your individual risk and benefit profile, not one who reflexively dismisses HRT or prescribes it without explanation. The conversation about HRT should include your symptom burden, your personal and family medical history, your preferences about delivery route and progestogen type, and your views on the risk-benefit tradeoffs involved. JourneyDoctors connects you with trained specialists from $19. Start a consultation today — no waiting room, no referral needed.

Disclaimer: This article is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for diagnosis and treatment.

Frequently Asked Questions

Does HRT cause weight gain?

Clinical trial data do not show that HRT causes weight gain; in fact, the Women's Health Initiative found no significant weight difference between HRT users and placebo groups. The weight changes many women notice around menopause are driven by age-related metabolic shifts and changes in body composition (increased fat, reduced muscle mass) rather than HRT. Some women report that HRT helps maintain body composition by preserving muscle mass and reducing central fat accumulation, which is associated with estrogen deficiency.

Can I use HRT if I have a BRCA mutation?

Women with BRCA1 or BRCA2 mutations who undergo risk-reducing bilateral salpingo-oophorectomy (preventive removal of ovaries and tubes) before natural menopause face a medically induced menopause that carries significant short-term and long-term health consequences. Current evidence and the guidance of major menopause societies support the use of HRT up to the age of natural menopause in these women, as the risks of premature estrogen deficiency outweigh the incremental HRT-related breast cancer risk in this context. This decision should always be made with a specialist team familiar with hereditary cancer management.

What is the difference between HRT and the contraceptive pill?

Menopausal HRT contains much lower doses of estrogen than combined oral contraceptives. The estrogen dose in a standard HRT preparation is typically 1 to 2 mg of oral estradiol or 50 micrograms of transdermal estradiol, compared to 20 to 35 micrograms of ethinyl estradiol in most low-dose contraceptive pills. Ethinyl estradiol is also a more potent synthetic estrogen with stronger hepatic effects than the natural estradiol used in most modern HRT. The two should not be conflated when discussing risk.

Can HRT help my mood?

Yes, for many women. Estrogen has direct effects on serotonin, dopamine, and norepinephrine systems. Perimenopausal and early menopausal depression and anxiety, when driven by hormonal fluctuation, often respond better to estrogen than to antidepressants alone. However, HRT is not an antidepressant in the clinical sense, and women with a pre-existing depressive disorder may need both HRT and a dedicated psychiatric treatment. Careful clinical assessment distinguishes hormonally-driven mood changes from primary mood disorders.

Does HRT protect the heart?

The answer depends critically on when HRT is started. In women who begin HRT within 10 years of menopause onset or before age 60, multiple lines of evidence including re-analyses of WHI data, the KEEPS trial, and the Danish Osteoporosis Prevention Study suggest neutral-to-protective cardiovascular effects. Starting HRT more than 10 years after menopause in women who already have established cardiovascular disease shows no benefit and possible harm. Transdermal estrogen has a more favorable cardiovascular profile than oral estrogen due to the absence of first-pass hepatic effects.